Lester Robert M, Paglialunga Sabina
Celerion Inc., Tempe, Arizona, USA.
Clin Transl Sci. 2025 Mar;18(3):e70145. doi: 10.1111/cts.70145.
Electrocardiogram (ECG) interpretation and measurement is an essential aspect of patient safety and pharmacovigilance in clinical trials. Changes in the T wave segment of an ECG can provide both diagnostic and prognostic information and may be affected by a variety of intrinsic and extrinsic factors related to drug administration. To add, regulators in their guidance encourage sponsors to provide analysis on treatment-emergent T wave morphology changes when submitting clinical study reports. Despite the T wave representing an important element of an ECG and impacting QT interval measurement, there is often a lack of recognition and incomplete understanding of the different T wave configurations that would affect subject management. Moreover, this topic has not been formally incorporated in pharmaceutical research. Therefore, this comprehensive review aims to profile normal and abnormal T wave morphologies that scientists and principal investigators might encounter during study conduct that would influence patient management and safety. This includes commentary on T wave pathophysiology, prognostic information, and short- and long-term management strategies when T wave abnormalities are present.
心电图(ECG)解读与测量是临床试验中患者安全和药物警戒的重要方面。心电图T波段的变化可提供诊断和预后信息,且可能受到与药物给药相关的多种内在和外在因素的影响。此外,监管机构在其指南中鼓励申办者在提交临床研究报告时,对治疗中出现的T波形态变化进行分析。尽管T波是心电图的重要组成部分并影响QT间期测量,但对于会影响受试者管理的不同T波形态,人们往往缺乏认识且理解不全面。此外,该主题尚未正式纳入药物研究。因此,本综述旨在概述科学家和主要研究者在研究过程中可能遇到的、会影响患者管理和安全的正常和异常T波形态。这包括对T波病理生理学、预后信息以及出现T波异常时的短期和长期管理策略的评论。